John Greenbaum, MBA

President of Generic Devices Consulting, Inc, a Regulatory Affairs, Clinical Research and Quality Assurance consulting firm specializing in Medical Devices, Biotechnology, Pharmaceuticals and Diagnostics. John has 20+ years of successful regulatory consulting experience having brought hundreds of therapeutic and diagnostic products to market, as well as medical devices. He is a seasoned executive, meticulous expert of clinical research operations, studies, and trials with FDA, EU, ISO, and ICH regulations, standards, and guidelines. In his career, John established QA, training, auditing, and standard operating procedures (SOP), liaising across the organization to align operations and trial / study efforts. Prior to founding Generic Devices Consulting, John was Vice President of St. Jude Medical, leading all quality and regulatory functions spanning multiple facilities and focusing on regulatory compliance matters and new product approvals, clinical trial design and performance. In 1992, he founded Metamed, INC and lead it through its acquisition from HealthWatch in 1993 (completed in 1994), where he served as a President and CEO, and brought it through the clinical studies and regulatory approval. Previously, he served as a President and CEO of Colorado MedTech, Inc., guiding the company formation from the merger of RELA and Cybermedic Inc. Prior to that he worked for 9 years at Eli Lilly & Company, in several positions: Director of Product Development, Director of Manufacturing and Engineering and Director of Quality Assurance, Regulatory and Clinical Affairs. John graduated with a Bachelor in Business Administration from Florida International University and an executive MBA at Babson College and Harvard University. He also pursued an executive training in Food and Drug Law at the Food and Drug Law Institute.

Saverio Cinti, MD

Professor at Polytechnic University of Marche (Ancona, Italy), where he coordinates different courses among which the integrated anatomy course at the Medicine and Surgery Degree and the Nourishment Degree. His main research topics are mammalian adipose organ (with brown adipocytes, organogenesis, functional anatomy, plasticity, transdifferentiation), Diabetes, Metabolic Syndrome, Obesity, Nutrition, Insulin Resistance and tissue engineering. He is author of the “Use of isolated mature adipocytes in regenerative medicine for tissue renewal and repair” patent (Italian Patent Deposit MI2008A001464), a book entitled “The adipose organ”, chapters in 13 books, more than 260 original publications on international journals with peer reviewers and he had more than 12,600 citations of the published work (Scopus June 2015 Author ID: 7004604501) with an H index of 51 (Scopus June 2015 Author ID: 7004604501).
The most recent awards received are Friedrich Wassermann Prize European Association for the Study of Obesity (EASO) (2013 - http://www.easo.org/easo) and the selection for the lecture at the world congress of International Federation Associations of Anatomists for the EFEM (European Federation Experimental Morphology) (2014 Beijin - http://www.csas.org.cn/ifaa2014). Dr. Cinti is the worldwide expert in adipose tissue.

Scott Guelcher, Ph.D.

Associate Professor of Chemical and Biomolecular Engineering at Vanderbilt University School of Engineering (TN, USA). After completing his B.S. degree in Chemical Engineering at Virginia Tech, Dr. Guelcher worked in the Research Division of Eastman chemical Company in Kingsport, TN on a number of projects in chemical and nutraceutical processing. He subsequently completed his Ph.D. with Professor John Anderson in Chemical Engineering at Carnegie Mellon University, where his dissertation work focused on investigating the electric field-induced motion of colloidal particles deposited near an electrode. Prior to his appointment at Vanderbilt, Dr. Guelcher was a Senior Associate Scientist in the Polyurethanes Division at Bayer Corporation and an NIH NRSA Fellow in the Department of Biomedical Engineering at Carnegie Mellon University where he worked with Professor Jeffrey Hollinger in bone tissue engineering. Professor Guelcher joined Vanderbilt University in 2005, and opened the Biomaterials and Tissue Engineering Laboratory in January 2006. He is author of more than 160 peer-reviewed scientific papers and inventor of 26 patents. Dr. Guelcher is a renown expert in the design, synthesis, and characterization of polymeric biomaterials for bone tissue engineering (with synthetic scaffolds)

Mario Rietjens, MD

Plastic Surgeon: Director of the Division of Reconstructive Surgery at the European Institute of Oncology (IEO). He graduated in Medicine and Surgery at the University do Estado de Sao Paulo (Unesp) of Botucatu (Brazil) and specialized in general oncology surgery at the Pio XII Foundation of Barretos (Brazil). He also graduated and specialized in plastic surgery at the University of Milan. At IEO he performs clinical researches in the field of Plastic Reconstruction Surgery, mainly in the development of new techniques, such as lipofilling, mammal repairing after a reconstructive surgery following removal caused by neoplasy. He is the referent of a clinical study aimed at evaluating the time of degeneration of silicone-gel mammal prostheses according to the time of implant. He participates in a new European study for the development of the use of the stem cells of adipose origin for the mammal repairing after quadrantectomy or mastectomy.

Cristina Lenardi, Ph.D

Researcher Associate in Physics: Cristina Lenardi is graduated in Physics at the University of Trieste and received her doctorate degree from the Politecnico of Milan. She is researcher at Dept. of Molecular Science Applied to Biosystems of Pharmacy Faculty and at the Center of Excellence CIMaINa of the University of Milan. Since 2009 she is the Head of Advanced Biomaterials platform at Fondazione Filarete. Her area of research focuses on biomaterials microfabrication techniques for the control of cell growth and stimuli aiming to mimic complex biochemistries and geometries of the extracellular matrix. She is author of about 85 papers on peer-reviewed journals, one book and two patents. She received a prize award from the G. Galileo Foundation and the “L. Tartufari” prize awarded by the Lincei National Academy.

Lucio Fumi

Lucio Fumi, MD, is a geriatrician who has worked for over thirty years in the healthcare industry in Italy, Germany, Slovenia, the UK and the Netherlands. Fully registered for Medical Practice in Italy and the UK, Lucio has worked as medical director of international corporations, to include Baxter, Abbott, Terumo and Bristol-Myers Squibb, with pharmaceutical, biotech, clinical nutrition and medical technology products.

In 1998 Lucio set up Wyfold Medical, a consultancy agency dedicated to medical affairs and clinical development for the medical device and biotech industry. As interim manager, Lucio worked as medical director or Chief Medical Officer of BioPheresis, RanD Biotech, Astellas Pharma, Clasado Biosciences, and BTG. More recently he was Chairman of the Board of BetaGlue Technologies (2016-18) and President of the Italian Medical Society of Great Britain (2014-16).